Statins and sepsis: panacea or Pandora's box? - Authors' reply

Lancet Infectious Diseases

Volumn 7, Issue 2, 2007, Pages 80-81

  Terblanche, Marius ^a   Almog, Yaniv ^b   Rosenson, Robert S ^c   Hackam, Daniel G ^d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; HUMAN; LETTER; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SEPSIS; CONTROLLED CLINICAL TRIAL; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; SEPSIS; SIMVASTATIN;

EID: 33846454336     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(07)70004-X     Document Type: Letter

References (4)

1. Rosenson R. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
2. de Lemos J., Blazing M., Wiviott S., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase z of the a to z trial. JAMA 292 (2004) 1307-1316
3. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
4. Newman C., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 92 (2003) 670-676